



# The TIMI Trials

## A to Z-TIMI 21

### **OBJECTIVES:**

**To determine if early aggressive treatment with simvastatin compared to standard therapy reduces major cardiac events at 1 year in high-risk acute coronary syndrome patients.**

**To determine the safety and efficacy of enoxaparin compared to unfractionated heparin when given to patients with acute coronary syndromes also receiving the GP IIb/IIIa inhibitor tirofiban.**

1. Blazing MA, de Lemos JA, Dyke C, Califf R, Braunwald E, Billheimer D. The A-to-Z trial: methods and rationale for a single trial that investigates the combined use of low-molecular weight heparin with GP IIB/IIIA inhibitor tirofiban and determines the efficacy of early aggressive simvastatin therapy. *Am Heart J* 2001; 142: 211-7.
2. Blazing MA, deLemos JA, White HD, Fox KAA, DiBattiste PM, Califf RM, Braunwald E for the A to Z investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. Randomized controlled trial. *JAMA* 2004;292:55-64.
3. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E for the A to Z Investigators. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes - Phase Z of the A to Z Trial. *JAMA* 2004;292:1307-1316.
4. de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KAA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E for the A to Z Investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. *Eur Heart J* 2004;25:1688-94.
5. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald E for the A to Z investigators. Prognostic value of serial B-type natriuretic peptide during follow-up of patients with unstable coronary artery disease. *JAMA* 2005;294:2866-71.
6. Morrow DM, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation* 2006;114:281-8.
7. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: Results from the A to Z trial. *J Am Coll Cardiol* 2007;50:2117-24.